华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688363 华熙生物

已收盘 04-30 15:00:02

{"stockData":{"symbol":"688363","market":"SH","secType":"STK","nameCN":"华熙生物","latestPrice":41.35,"timestamp":1777532402000,"preClose":43.35,"halted":0,"volume":5190891,"delay":0,"changeRate":-0.0461,"floatShares":482000000,"shares":482000000,"eps":0.5291,"marketStatus":"已收盘","change":-2,"latestTime":"04-30 15:00:02","open":42,"high":42.08,"low":41.22,"amount":215000000,"amplitude":0.0198,"askPrice":41.36,"askSize":50,"bidPrice":41.35,"bidSize":300,"shortable":0,"etf":0,"ttmEps":0.5291,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778031000000},"marketStatusCode":5,"adr":0,"adjPreClose":43.35,"symbolType":"stock_kcb","openAndCloseTimeList":[[1777512600000,1777519800000],[1777525200000,1777532400000]],"highLimit":47.69,"lowLimit":39.02,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":481678242,"isCdr":false,"pbRate":2.79,"roa":"--","peRate":78.151578,"roe":"0.91%","epsLYR":0.61,"committee":-0.267364,"marketValue":19917000000,"turnoverRate":0.0108,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-05-06。","afterMarket":{"amount":0,"volume":0,"close":41.35,"buyVolume":0,"sellVolume":0,"time":1777534437559,"indexStatus":"已收盘 04-30 15:30:00","preClose":43.35},"floatMarketCap":19917000000},"requestUrl":"/m/hq/s/688363","defaultTab":"news","newsList":[{"id":"2631655194","title":"华熙生物（688363）披露提请股东会授权董事会以简易程序向特定对象发行股票的公告，4月30日股价下跌4.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631655194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631655194?lang=zh_cn&edition=full","pubTime":"2026-04-30 22:05","pubTimestamp":1777557925,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，华熙生物报收于41.35元，较前一交易日下跌4.61%，最新总市值为199.17亿元。华熙生物科技股份有限公司于2026年4月29日召开第三届董事会第七次会议，审议通过《关于提请股东会授权董事会以简易程序向特定对象发行股票的议案》。本次发行股票限售期为六个月或十八个月。该事项尚需提交股东会审议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000068286.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631387516","title":"华熙生物最新公告：第一季度净利润同比下降36.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631387516","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631387516?lang=zh_cn&edition=full","pubTime":"2026-04-29 19:49","pubTimestamp":1777463385,"startTime":"0","endTime":"0","summary":"华熙生物(688363.SH)公告称，2026年第一季度实现营业收入8.29亿元，同比下降23.06%；归属于上市公司股东的净利润为0.65亿元，同比下降36.55%。业绩变动主要系皮肤科学创新转化业务收入同比下降所致。注：公司Q1净利润0.65亿，2025年Q4净利润0.4亿，据此计算，Q1净利润环比增长62%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900060792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804976","title":"每周股票复盘：华熙生物（688363）2025年净利增67.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804976","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804976?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:50","pubTimestamp":1777146622,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，华熙生物报收于42.75元，较上周的43.2元下跌1.04%。本周关注点来自业绩披露要点：华熙生物2025年归母净利润2.92亿元，同比上升67.59%。股本股东变化截至2026年3月31日，华熙生物股东户数为3.18万户，较2025年12月31日增加219.0户，增幅0.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629850883","title":"股市必读：华熙生物年报 - 第四季度单季净利润同比增长121.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629850883","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629850883?lang=zh_cn&edition=full","pubTime":"2026-04-24 03:43","pubTimestamp":1776973400,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日华熙生物披露，截至2026年3月31日公司股东户数为3.18万户，较12月31日增加219.0户，增幅为0.69%。公司公告汇总华熙生物2025年年度报告摘要华熙生物2025年年度报告摘要显示，公司实现营业收入41.99亿元，同比下降21.82%；归属于上市公司股东的净利润为2.92亿元，同比增加67.59%；归属于上市公司股东的扣除非经常性损益后的净利润为1.86亿元，同比增加73.76%；经营活动产生的现金流量净额为6.27亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400009687.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629045540","title":"华熙生物最新公告：2025年净利润2.92亿元同比增长67.59%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629045540","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629045540?lang=zh_cn&edition=full","pubTime":"2026-04-22 19:40","pubTimestamp":1776858058,"startTime":"0","endTime":"0","summary":"华熙生物(688363.SH)发布2025年年度报告，实现营业收入41.99亿元，同比下降21.82%；归属于上市公司股东的净利润为2.92亿元，同比增长67.59%。公司拟向全体股东每10股派发现金红利1.90元(含税)。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200048238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629090949","title":"国货美妆品牌抢占线下折扣店","url":"https://stock-news.laohu8.com/highlight/detail?id=2629090949","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629090949?lang=zh_cn&edition=full","pubTime":"2026-04-22 15:24","pubTimestamp":1776842640,"startTime":"0","endTime":"0","summary":"国货美妆品牌抢占线下折扣店","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604223713962495.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604223713962495.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0196","LU1146622755.USD","BK0239","LU0274383008.USD","LU2488822045.USD","LU1997245094.SGD","LU1997245177.USD","BK0028","02367","688363","BK0188","SG9999004311.SGD","BK0229","BK1207","BK0273","LU1820825898.SGD","300957","BK0012","LU0593848301.USD","600315","301371","BK0070","600223","603605","IE0005HP3H50.USD","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621777168","title":"破发股华熙生物跌5.81%创新低 2019年上市募23.69亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2621777168","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621777168?lang=zh_cn&edition=full","pubTime":"2026-03-23 17:29","pubTimestamp":1774258151,"startTime":"0","endTime":"0","summary":"中国经济网北京3月23日讯 华熙生物 今日收报40.50元，跌幅5.81%。华熙生物今日盘中股价最低至40.36元，创历史新低。该股目前处于破发状态。　　2019年11月6日，华熙生物在上交所科创板上市，发行价格为47.79元/股，募集资金总额为23.69亿元，扣除发行费用后，募集资金净额为22.49亿元。华熙生物的发行费用合计为 11,964.01 万元，其中保荐及承销费等为9,666.00万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260323/32090564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619344024","title":"玻尿酸王座崩塌：华熙生物从1400亿到217亿的生死突围","url":"https://stock-news.laohu8.com/highlight/detail?id=2619344024","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619344024?lang=zh_cn&edition=full","pubTime":"2026-03-16 14:40","pubTimestamp":1773643239,"startTime":"0","endTime":"0","summary":"文｜《思维深潜研究组》2026 年 2 月末，华熙生物 2025 年业绩快报落地：全年营收 42.17 亿元，同比下滑 21.49%；归母净利润 2.91 亿元，同比大增 67.03%。流量驱动、多品牌分散、渠道价格混乱，叠加行业退潮，华熙从神坛跌落，当前市值约 217 亿元。玻尿酸基本盘之外，胶原蛋白、聚乳酸、合成生物学、再生材料决定未来市值。华熙生物的起落、三强的鏖战、C 端的突围、全球化的起步，共同构成中国制造向中国品牌升级的缩影。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1773563588661892485","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0229","688363","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617663216","title":"华熙生物公布国际专利申请：“油性组合物及其用途”","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663216","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663216?lang=zh_cn&edition=full","pubTime":"2026-03-08 05:16","pubTimestamp":1772918181,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示华熙生物（688363）公布了一项国际专利申请，专利名为“油性组合物及其用途”，专利申请号为PCT/CN2025/116285，国际公布日为2026年3月5日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来华熙生物已公布的国际专利申请2个，较去年同期增加了100%。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.31亿元，同比增15.25%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363","BK0239","BK0229"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616333262","title":"华熙生物2025年营收42亿：同比降21% 净利2.9亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2616333262","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616333262?lang=zh_cn&edition=full","pubTime":"2026-03-02 20:55","pubTimestamp":1772456102,"startTime":"0","endTime":"0","summary":"华熙生物（证券代码：688363）日前发布2025年业绩快报，业绩快报显示，华熙生物2025年营收42.17亿，较上年同期的53.71亿元降21.49%。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260302/6390808169942304828177013.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260302/6390808169942304828177013.jpeg"],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n32767/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616488843","title":"每周股票复盘：华熙生物（688363）净利增67.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616488843","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616488843?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:13","pubTimestamp":1772302390,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，华熙生物报收于47.36元，较上周的47.25元上涨0.23%。本周，华熙生物2月25日盘中最高价报48.82元。华熙生物当前最新总市值228.12亿元，在医疗美容板块市值排名2/3，在两市A股市值排名977/5189。本周关注点业绩披露要点：华熙生物2025年归属净利润同比增长67.03%。公司公告汇总华熙生物发布2025年度业绩快报，营业总收入为42.17亿元，同比下降21.49%；归属于母公司所有者的净利润为2.91亿元，同比增长67.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688363","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614897643","title":"营收跌21%、净利却大增近七成！华熙生物“断臂求生”见效","url":"https://stock-news.laohu8.com/highlight/detail?id=2614897643","media":"市场资讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614897643?lang=zh_cn&edition=full","pubTime":"2026-02-28 13:30","pubTimestamp":1772256600,"startTime":"0","endTime":"0","summary":"　　2月27日晚间，华熙生物发布2025年度业绩快报称，报告期内，公司实现营业收入42.17亿元，与上年同期的53.71亿元相比减少了21.49%；实现归属于母公司所有者的净利润2.91亿元，比上年同期增加67.03%；实现归属于母公司所有者的扣除非经常性损益的净利润1.88亿元，比上年同期增加75.28%。报告期末总资产86.55亿元，较期初下降0.02%；归属于母公司的所有者权益70.84亿元，较期初增加 4.02%。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-02-28/doc-inhpiwhn3009086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614835062","title":"华熙生物发布2025年度业绩快报，盈利2.911亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614835062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614835062?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:24","pubTimestamp":1772184270,"startTime":"0","endTime":"0","summary":"证券之星消息，华熙生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润盈利2.911亿元，同比增长67.03%。华熙生物主营业务：华熙生物是全球领先的、以透明质酸微生物发酵生产技术为核心的高新技术企业,透明质酸产业化规模位居国际前列。该股最近90天内共有7家机构给出评级，买入评级4家，增持评级2家，中性评级1家；过去90天内机构目标均价为54.28。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700029045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0229","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614011355","title":"华熙生物赵燕：支持科技抗衰，但坚决反对改头换面的大手术医美","url":"https://stock-news.laohu8.com/highlight/detail?id=2614011355","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614011355?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:42","pubTimestamp":1772098920,"startTime":"0","endTime":"0","summary":"　　在对话中，华熙生物董事长赵燕谈及“自然美和医美”时表示，只要是自己认可的都是美。但是，她明确表示反对“改头换面的大手术医美”。　　赵燕谈到，用现代的一些科技手段、科技产品，能对自己的衰老做一些干预，让自己更年轻，从而更自信，心态也能回到年轻的状态，这个还是非常认的。　　赵燕表示，不排除市场上有一些医美机构过度放大了焦虑。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-02-26/doc-inhpcusk4403266.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688363","BK0229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614019156","title":"年轻人活得比较自我？华熙生物赵燕：这没做错","url":"https://stock-news.laohu8.com/highlight/detail?id=2614019156","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614019156?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:27","pubTimestamp":1772098020,"startTime":"0","endTime":"0","summary":"　　在对话中，华熙生物董事长赵燕表示，和年轻人在一起的时候，除了好奇、勇气和坚韧，还需要了解到他们在关注什么，认真去分析底层原因。　　赵燕强调，尤其是企业做研发，一定要观察现在有哪些消费者的需求是未被满足的，而且一定要能够打动他的情绪连接点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-02-26/doc-inhpcusf0504873.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0229","688363","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614150570","title":"华熙生物赵燕：医美让人重拾自信，优雅变老","url":"https://stock-news.laohu8.com/highlight/detail?id=2614150570","media":"睿见Economy","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614150570?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:08","pubTimestamp":1772096880,"startTime":"0","endTime":"0","summary":"　　赵燕表示，大家都认为衰老是一个自然过程，但是在生命科学领域来说，衰老是能够被主动干预和控制的过程。华熙生物的使命，是让每个生命都是鲜活的，所以要提高生命质量，让人活得长。“医美说到底，是让人重拾自信，尤其对于女性，能够很优雅地变老，更多的是一个心理上的慰藉。”","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/hy/hyjz/2026-02-26/doc-inhpcusf0489597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0229","688363","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608885712","title":"股市必读：华熙生物（688363）预计2025年全年归属净利润盈利2.7亿元至3.2亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608885712","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608885712?lang=zh_cn&edition=full","pubTime":"2026-02-02 01:50","pubTimestamp":1769968223,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，华熙生物报收于44.83元，下跌3.2%，换手率0.96%，成交量4.64万手，成交额2.1亿元。来自公司公告汇总：华熙生物预计2025年扣非后净利润同比增长55.68%至102.29%，业绩增长主要源于组织架构优化与运营成本下降。业绩披露要点业绩预告华熙生物发布业绩预告，预计2025年全年归属净利润盈利2.7亿元至3.2亿元；扣非后净利润盈利1.67亿元至2.17亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200000859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607377041","title":"华熙生物（688363）披露2025年年度业绩预增公告，1月30日股价下跌3.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607377041","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607377041?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:27","pubTimestamp":1769783240,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，华熙生物报收于44.83元，较前一交易日下跌3.2%，最新总市值为215.94亿元。该股当日开盘46.61元，最高46.61元，最低44.83元，成交额达2.1亿元，换手率为0.96%。近日，华熙生物科技股份有限公司发布2025年年度业绩预增公告。公告显示，公司预计2025年年度实现归属于母公司所有者的净利润27,000.00万元到32,000.00万元，同比增加54.93%到83.63%；扣除非经常性损益的净利润16,700.00万元到21,700.00万元，同比增加55.68%到102.29%。上年同期净利润基数较小，进一步放大增幅。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047342.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","BK0239","688363"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607709867","title":"可以让人活到120岁！华熙生物董事长回应争议言论","url":"https://stock-news.laohu8.com/highlight/detail?id=2607709867","media":"快科技","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607709867?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:39","pubTimestamp":1769737196,"startTime":"0","endTime":"0","summary":"快科技1月30日消息，此前，华熙生物董事长、总裁赵燕曾公开表示：“让人能够健康，能蹦能跳，能吃能睡的活到超过120岁”，该言论也引发网络热议。昨晚在“企业家之夜”活动上，她再次回应此事。在她看来，未来10年由于科技的发展，重大疾病将要被解决掉。官网显示，华熙生物成立于2000年，公司率先实现抗衰核心物质透明质酸的生物制造，市场份额常年全球第一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://tech.ifeng.com/c/8qKaGjQKJlf","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fenghuang_stock","symbols":["688363","BK0229","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605281761","title":"华熙生物公布国际专利申请：“一种Cas蛋白及其基因编辑系统和应用”","url":"https://stock-news.laohu8.com/highlight/detail?id=2605281761","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605281761?lang=zh_cn&edition=full","pubTime":"2026-01-24 08:50","pubTimestamp":1769215844,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示华熙生物（688363）公布了一项国际专利申请，专利名为“一种Cas蛋白及其基因编辑系统和应用”，专利申请号为PCT/CN2025/107574，国际公布日为2026年1月15日。专利详情如下：图片来源：世界知识产权组织（WIPO）今年以来华熙生物已公布的国际专利申请1个，与去年同期持平。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了2.31亿元，同比增15.25%。数据来源：企查查以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012400011761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0229","688363","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1777577982031,"stockEarnings":[{"period":"1week","weight":-0.0381},{"period":"1month","weight":0.011},{"period":"3month","weight":-0.0776},{"period":"6month","weight":-0.2341},{"period":"1year","weight":-0.1516},{"period":"ytd","weight":-0.0533}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":0.0566},{"period":"3month","weight":-0.0014},{"period":"6month","weight":0.0398},{"period":"1year","weight":0.2541},{"period":"ytd","weight":0.0361}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"华熙生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"31791人(较上一季度增加0.69%)","perCapita":"15151股","listingDate":"2019-11-06","address":"山东省济南市历下区高新技术开发区天辰大街678号","registeredCapital":"48167万元","survey":"　　华熙生物科技股份有限公司的主营业务是研发、生产和销售透明质酸等生物活性物质原料产品及生物医用材料终端产品。公司的主要产品是原料产品、医疗终端产品、皮肤科学创新转化业务。公司坚持科技创新驱动发展，科技创新能力多次获得国家及各级政府认可。公司先后被认定为国家企业技术中心、国家药监局化妆品原料质量控制重点实验室（联合申报）、山东省生物活性物合成生物学重点实验室、海南省再生医学技术与材料转化重点实验室、天津市生物合成与过程工程重点实验室、糖类智造及功能应用北京市重点实验室等科研平台，并参与共建国家合成生物技术创新中心及国家生物制造产业创新中心。凭借在技术创新和产业引领方面的突出表现，公司获得国家制造业单项冠军示范企业、国家知识产权优势企业、山东省科技进步一等奖、山东省省长质量奖、中国商业联合会特等奖等多项国家级、省级荣誉。","listedPrice":47.79},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供华熙生物(688363)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"华熙生物,688363,华熙生物股票,华熙生物股票老虎,华熙生物股票老虎国际,华熙生物行情,华熙生物股票行情,华熙生物股价,华熙生物股市,华熙生物股票价格,华熙生物股票交易,华熙生物股票购买,华熙生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"华熙生物(688363)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供华熙生物(688363)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}